摘要:
Methods of treating and/or diagnosing irritable bowel syndrome (IBS) are provided, wherein treatment or diagnosis is undertaken on the basis of the patient's recordation of events associated with IBS in an event log and/or symptom diary.
摘要:
The present invention relates to a method of improving intensive care unit (ICU)-associated hypocalcemia in a mammal by the administration of a vitamin D compound, or other compounds exhibiting vitamin D-like activity, to the mammal for a sufficient period of time to improve or restore the serum calcium levels of the mammal.
摘要:
The present invention relates to oral formulations comprising paricalcitol that are available in a variety of different dosage forms that are bioequivalent to one another.
摘要:
Methods for treating mammals before, during and after cardiac arrest are disclosed. Pharmaceutical compositions comprising levosimendan useful for such treatment also are disclosed.
摘要:
Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to the invention include a VDRA/Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.
摘要:
The invention relates to a method of administering an inotropic agent (such as, but not limited to, a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders.
摘要:
The invention relates to intermittent administration of an inotropic agent (such as, but not limited to a levosimendan compound) or a pharmaceutically acceptable salt thereof in the treatment of cardiovascular disorders, such as, pulmonary hypertension, myocardial ischemia, acute heart failure, chronic heart failure or acute on chronic heart failure.
摘要:
Disclosed are compositions containing a VDRA/Vitamin D analog to treat or prevent kidney disease, including chronic kidney disease. The present invention also relates to methods of treating kidney disease by administering to a patient a pharmaceutical composition containing a therapeutically effective amount of a VDRA/Vitamin D analog. Compositions according to the invention include a VDRA/Vitamin D analog and at least one of the following agents: an ACE inhibitor, an angiotensin (II) receptor blocker (ARB) and aldosterone blocker in therapeutically effective amounts to inhibit renin production or inhibit activation of the renin-angiotensin-aldosterone system. Preferred compositions contain paricalcitol with at least one of these other agents. Such combinations can avoid ACE inhibition escape and aldosterone escape with subsequent increase in angiotensin (II) and aldosterone generation.